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ABSTRACT We have characterized a strain of double
transgenic mice with simian virus 40 large tumor antigen and
prokaryotic lacZ under the control of the myelin basic protein
promoter that develops spindle-cell sarcomas and osteogenic
sarcomas at 5-7 months of age. Although poorly differentiated,
the spindle-cell sarcomas were characterized as malignant
Schwannomas based on their neural association, the presence
of basal lamina, and expression of Schwann cell-specific genes.
The osteogenic sarcomas were often multiple and appeared
predominantly in the facial bones, less frequently in the ribs
and vertebral column, and only rarely in the appendicular
skeleton. Benign osteoblastic lesions were often observed ad-
jacent to these sarcomas. Both the osteoblastic cells in the facial
skeleton and Schwann cells are regarded as neural crest
derivatives. The biological properties and anatomical location
of these tumors suggest that they may share a common origin
from the neural crest or its derivatives. R. P. Bolande [Hum.
Pathol. (1974) 5, 409-429] introduced the term neurocristop-
athy as a unifying concept to describe such lesions arising from
the neural crest or its derivatives. CeDl lines established from
both bone and Schwann cell tumors arising in these transgenic
mice express simian virus 40 large tumor antigenmRNA as well
as functional large tumor antigen. Such cell lines are potentially
valuable in the search for markers that identify mammalian
neural crest derivatives.
Tumorigenesis is generally regarded as a multifactorial pro-
cess that requires the accumulation of synergistic mutations
in a number of genes involved in diverse biochemical pro-
cesses such as cell division, differentiation, DNA repair,
angiogenesis, and metastasis. Oncogenesis can be induced in
transgenic mice harboring tumor-promoting genes, and, de-
pending on the regulatory sequences governing transgene
expression, tumors can be induced in either multiple tissues
or in a single tissue (1).
In transgenic mice, the simian virus 40 (SV40) large tumor
antigen (T antigen) is generally a potent carcinogen. This
activity involves functional inactivation of the ubiquitously
expressed tumor suppressor proteins p53 and pRb. The p53
protein, by arresting cells with damaged or mutated DNA in
the G1 phase of the cell cycle, is thought to constitute a
checkpoint in DNA repair (2). In T-antigen-transformed
cells, functional inactivation of p53 seems to be a major
determinant of karyotype instability and an important check-
point that must be bypassed in the clonal evolution of
preneoplastic cells.
Mice harboring SV40 T antigen and prokaryotic lacZ under
the control of the mouse myelin basic protein (MBP) pro-
moter (MBP-SV40 T antigen and MBP-lacZtransgenic mice)
are described elsewhere (3). The majority of these mice
developed distinct hypomyelinated phenotypes. However,
transgenic mice of the double transgenic strain Tn29 dis-
played a normal phenotype until about 5 months of age, when
they present with tumors. Here we report that these tumors
are malignant Schwannomas and osteogenic sarcomas (i.e.,
malignant mesenchymal tumors, which form bone). Interest-
ingly, the facial bones appeared to be the most frequent site
for both osteogenic sarcomas and preneoplastic osteoblastic
lesions. A majority ofbone-forming cells in this portion ofthe
skeleton, like Schwann cells, are derived from the neural
crest (4, 5). Thus, transgenic mice of strain Tn29 represent an
interesting model for neurocristopathy-a concept intro-
duced by Bolande (6) to describe lesions arising from alter-
ations in migration, growth, and differentiation of cells de-
rived from the neural crest.
MATERIALS AND METHODS
Transgenic Mice. The transgenic founder Tn29 was gener-
ated by microinjection ofDNA containing purified fragments
of two recombinant DNA constructs, MBP-SV40 T antigen
and MBP-lacZ, into the pronucleus of fertilized mouse eggs
(3). Tail DNA was prepared and transgenic mice were
identified by blot analysis with SV40 T antigen- and lacZ-
specific hybridization probes.
Histology and Electron Microscopy. Mice were sacrificed
by an intraperitoneal overdose of tribromoethanol (Avertin)
and a complete postmortem examination was performed.
Fragments of tumors were processed for light and electron
microscopy (see below). After the brain was removed, the
facial skeleton was decalcified, sectioned in the coronal
plane, and embedded in toto. Multiple transverse sections of
the vertebral column, with the spinal cord intact, were also
examined. For light microscopy, tissues were fixed in neutral
phosphate-buffered 10%o formalin, embedded in paraffin, and
stained with hematoxylin and eosin. Sections were decalci-
fied in RDO (American Histology Reagent, Stockton, CA).
Fragments of tumor were also snap-frozen in liquid nitrogen-
cooled isopentane and stored at -80°C. For electron micros-
copy, small fragments of fresh tumor were fixed in ice-cold
Karnovsky's fixative (5% glutaraldehyde/4% paraformalde-
hyde), embedded in Epon, and examined with a Zeiss EM 109
electron microscope.
Cell Culture. Tumor fragments were removed aseptically
and single cell suspensions were obtained by trypsin treat-
ment for 30 min at 37°C. The tumor cells were cultured in
25-cm2 tissue culture flasks containing Dulbecco's modified
Eagle's medium (DMEM) (GIBCO) supplemented with 10%/o
fetal bovine serum (FBS) and antibiotics in the presence or
absence of dibutyryl-cAMP (DBC).
Northern Blot Analysis. Total RNA from tumor cell lines
was extracted by the isothiocyanate method as described (7).
For Northern blot analysis, the RNA was electrophoresed in
formaldehyde/agarose gels, blotted onto nitrocellulose mem-
Abbreviations: SV40, simian virus 40; T antigen, large tumor antigen;
MBP, myelin basic protein; FBS, fetal bovine serum; DBC, dibu-
tyryl-cAMP.
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branes, and hybridized with 32P-labeled nick-translated
probes.
Immunoprecipitation of SV40 T Antigen. Semiconfluent
cell cultures were incubated for 1 h in methionine-free
DMEM containing 10% FBS to deplete the internal methio-
nine pools before labeling. The cells were washed with PBS
and labeled with 500 ,uCi of [35S]methionine (1 Ci = 37 GBq)
(Tran35S-label; ICN) in 2 ml of methionine-free DMEM per
100-mm dish for 3-4 h with occasional rocking. At the end of
the incubation, the cells were washed once with PBS at
ambient temperature. The plates were drained to remove
excess PBS, placed on ice, and rocked intermittently for
20-30 min with 1 ml of prechilled lysis buffer (250 mM
NaCl/0.1% Nonidet P-40/50 mM Hepes, pH 7.0). The cells
were scraped from the plate with a rubber policeman, trans-
ferred to a microcentrifuge tube, and centrifuged for 10 min
at maximum speed at 4°C in an Eppendorf microcentrifuge.
Aliquots of the supernatant (300 ul) were mixed with 500 ,ul
of NET-N buffer (20 mM Tris HCl, pH 8.0/100 mM NaCl/1
mM Na2EDTA/0.1% Nonidet P-40) and 50 ,u of monoclonal
antibody 419 ascites fluid (gift from E. Harlow, Imperial
Cancer Research Fund Laboratories, London; this antibody
recognizes an N-terminal epitope of the T antigen). The
mixture was incubated at 4°C for at least 1 h with rocking,
after which immune complexes were precipitated with pro-
tein A-Sepharose (2 h at 4°C). The reacted protein A-Seph-
arose was washed five times with NET-N buffer, resus-
pended in 50 ,ul ofSDS sample buffer [2% SDS/10%o (vol/vol)
glycerol/62 mM Tris HCl, pH 6.8], boiled 5 min, and loaded
onto SDS/10%o polyacrylamide gels. The components of
immunoprecipitation were resolved by electrophoresis in
Tris glycine buffer together with prestained low and high
molecular weight protein standards (Bio-Rad).
RESULTS
Two Tumor Phenotypes in Strain 29 Transgenic Mice.
Southern blot analyses revealed that the MBP-SV40 T anti-
gen and MBP-lacZ transgenes exhibited autosomal Mende-
lian inheritance and cosegregated in all generations of Tn29
mice. Transgenic mice of this strain appeared normal until
about 5-7 months of age when tumors became apparent in
various locations (Table 1). Histological examination showed
these to be either poorly differentiated spindle cell sarcomas
or osteogenic sarcomas (Table 1; Fig. 1).
Schwann Cell Origin of Spindle Cell Sarcomas. A total of 23
transgenic mice were examined, and 12 malignant spindle cell
mesenchymal tumors (sarcomas) were present in 11 animals
(Table 1). Seven of these tumors arose within nerves-2 in
paravertebral spinal nerves and S in the trigeminal nerve (fifth
cranial nerve). The tumors infiltrated peripherally within the
perineurium and in several cases extended centrally to invade
Table 1. Summary of tumors and hyperplasia in strain 29 transgenic mice
Chondroblastic
Mouse Spindle cell sarcoma Osteogenic sarcoma Osteoblastic hyperplasia hyperplasia
18-45 Pelvis/thigh Rib (2) Rib
40-1 Paranasal sinus (2) Periodontal ligament Periodontal ligament
41-7 Chest wall; pelvis; rib (3)
42-11 Brain/choroid plexus; paranasal Paranasal sinus; periodontal ligament
sinus (2); vertebral body
(lumbar)
42-12 Paranasal sinus; rib Periodontal ligament; rib
42-14 Trigeminal nerve Maxilla; periodontal ligament (3); Paranasal sinus; rib
rib (2)
47-26 Paranasal sinus; periodontal
ligament; rib (2)
47-27 Axilla/shoulder
48-21 Scapula
56-22 Scapula Dorsal vertebral column Rib; vertebral body
(cervical); paranasal sinus; rib
(2)
56-23 Humerus; rib Rib
56-24 Chest wall Periodontal ligament; rib Periodontal ligament
60-28 Dorsal vertebral arch (cervical) Paranasal sinus; periodontal ligament Periodontal ligament
60-29 Intervertebral disc (lumbar); Periodontal ligament Periodontal ligament
paranasal sinus; periodontal
ligament; vertebral arch
(thoracic)
62-33 Palate; periodontal ligament Periodontal ligament
62-35 Trigeminal nerve Maxilla; periodontal ligament Paranasal sinus; periodontal ligament;
rib
64-39 Trigeminal nerve Periodontal ligament Paranasal sinus
65-41 Trigeminal nerve;
thoracic nerve
(paravertebral)
65-42 Thoracolumbar nerve
(paravertebral)
66-43 Adjacent to trigeminal nerve; Paranasal sinus; periodontal ligament
periodontal ligament
66-44 Paranasal sinus (2); periodontal Paranasal sinus; periodontal ligament
ligament
67-45 Trigeminal nerve Paranasal sinus (2); periodontal Paranasal sinus; periodontal ligament
ligament (2)
Numbers in parentheses indicate number of individual osteosarcomas observed in a particular anatomic structure.
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FIG. 1. Two types of tumor
arise in Tn29 transgenic mice. (a)
Mouse showing osteogenic sar-
coma (t) arising from right maxilla.
(b) Malignant Schwannoma aris-
ing in right trigeminal nerve (t).
Left trigeminal nerve (n) is nor-
mal. (c) Coronal section through
osteogenic sarcoma in a. Tumor
(t) is well circumscribed and arises
from the periosteal surface of the
maxilla. (x4.25.) (d) Coronal sec-
tion through trigeminal ganglia
showing malignant Schwannoma
(t) in trigeminal nerve, infiltrating
the surrounding soft tissues and
sphenoid bone. (x5.) (e) Abnor-
mal osteoblastic proliferation in
periodontal ligament. Periodontal
ligament (p) is hypercellular and
contains disarrayed osteoid with
adjacent hyperchromatic osteo-
blasts (t) near the alveolar bone.
Adjacent tooth is normal. (x 190.)
(f) Schwannoma showing uni-
form, malignant spindle cells ar-
ranged in interlacing bundles.
(x20.) (g) Osteogenic sarcoma
showing numerous disordered os-
teoid seams surrounded by malig-
nant osteoblasts. (x 190.) (h) Elec-
tron micrograph of malignant
Schwannoma showing basal lam-
ina material (arrow) and interdig-
itating cell processes. (x58,400.)
the subarachnoid space, and in one case the spinal cord (Fig.
1). In five cases, neural involvement could not be identified.
However, all 12 spindle cell tumors appeared remarkably
similar morphologically. Macroscopically, they were firm,
well circumscribed, and lobulated, displaying a white to
greyish cut surface. Microscopically, they were composed of
hypercellular nodules of uniform spindle-shaped cells (Fig.
lf). There were numerous mitoses and occasional foci of
necrosis. Although several tumors arose within nerves, no
features were observed that suggested Schwann cell differ-
entiation [i.e.-, compactly arranged spindle cells with parallel
long axes-Antoni type A pattern-or loosely arranged cells
widely separated by a clear matrix-Antoni type B pattern
(8)]. Blood vessels were not prominent. Four of the sarcomas
were examined by electron microscopy. All showed areas
with elongated cells and some interdigitating processes. In
addition, continuous and discontinuous basal lamina was
identified in 3 of the tumors (Fig. lh). These features are
consistent with, but not diagnostic of, Schwann cell differ-
entiation.
To investigate whether these tumors show Schwann cell
differentiation (e.g., express Schwann cell genes) we per-
formed Northern blot analyses on RNA extracted from
tumor-derived cell lines. Cell line 56-24 was established from
a spindle cell sarcoma that arose in Tn56-24 (Table 1) and
showed no definite neural association. In the absence of
DBC, 56-24 cells expressed moderate levels of mRNA en-
coding the major myelin proteins MBP and Po (Fig. 2). These
genes are expressed at substantial levels in myelin-forming
Schwann cells (9). A substantial downregulation ofMBP and
Po mRNA appeared after DBC stimulation (Fig. 2). In
contrast, the Schwann cell transcription factor SCIP (10, 11)
was upregulated in DBC-stimulated 56-24 cells compared to
unstimulated cells (Fig. 2). MBP mRNA was also detected in
another cell line, designated 64-39, established from a spindle
cell sarcoma arising from the trigeminal nerve of animal
i
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56-24
*S ;WO C; FIG. 2. Autoradiographs of
m 1.i : Northern blot analyses of MBP,
Po, and SCIP expression in un-
induced and DBC-induced cells
^ of the malignant Schwannoma
MBP cell line 56-24. Briefly, an early
passage of 56-24 cells was cul-
tured in DMEM containing 10%o
FBS. In the case of DBC stimu-
lation, the cells were cultured for
Po
* 3 days in the presence of 300 ,M
DBC before RNA purification.
Control RNA from brain and
liver was purified from an adult
nontransgenic mouse. Ethidium
SCIP bromide staining of 18S rRNA on
the two blots used for hybridiza-
tion indicates relative amounts of
total RNA (10 Mg per lane). (a)
Filter was used in hybridization
with MBP. (b) A second filter18SrRNA _ R1 - g- was used in successive hybrid-
b Sf XF+| izations with Po and SCIP
_ L X probes. All three probes were
32P-labeled.
Tn64-39 (Table 1; data not shown). Thus, expression of
Schwann cell-specific genes in spindle cell sarcoma-derived
cell lines confirms the Schwann cell origin of these tumors.
Osteogenic Sarcomas. A total of 48 osteogenic sarcomas
were found in 16 mice. Macroscopically, these tumors were
hard, rounded, and gray, and they appeared to originate from
the periosteal surface. In most cases, the underlying cortical
bone was normal and the medullary cavity contained hema-
topoietic marrow. The tumors ranged from well-differenti-
ated osteoblastic lesions with few mitoses, in which the tumor
cells (osteoblasts) synthesized large amounts of mature bone
(Fig. lg), to poorly differentiated hypercellular lesions with
sparse osteoid (uncalcified bone matrix), numerous mitotic
figures, and extensive areas of necrosis. Osteoclasts (bone-
resorbing cells) were demonstrated in 2 tumors.
In contrast to the malignant Schwannomas, the osteogenic
sarcomas were multiple and the majority, 26, involved the
facial bones including the walls of the nasal and paranasal
sinuses, the mandible, and maxilla (Table 1). In the jaw,
tumors arose from the alveolar bone and extended into the
periodontal ligament (Fig. le). Thirteen osteogenic sarcomas
arose from ribs and 5 involved the vertebral column. Only 1
tumor appeared in the appendicular skeleton (proximal hu-
merus; Table 1). In addition, 2 osteogenic sarcomas appeared
to arise within soft tissues with no obvious skeletal connec-
tion. One arose in the brain in the region of the fourth
ventricle and the other was adjacent to the trigeminal gan-
glion (Table 1).
Frequently, the periodontal ligament adjacent to the jaw
sarcomas was hypercellular, although the teeth and under-
lying bone appeared normal. Furthermore, a continuum from
hyperplasia to overt neoplasia could be observed at this site.
The rib osteogenic sarcomas were associated with a thick-
ened and hypercellular periosteum, which was most promi-
nent over the anterior surfaces of the ribs. As in the facial
tumors, a morphological continuum between osteoblastic
hyperplasia and osteosarcoma was often apparent.
Expression of Functional T Antigen in Tumor Cells. South-
ern blots indicated that strain 29 mice harbor full-length
copies of both injected transgenes (data not shown). Using
Northern blot analyses and immunostaining, we were unable
to detectT antigen and lacZ expression in the nervous system
of these mice (data not shown). However, the frequent
appearance of malignant Schwannomas suggests that the T
antigen was occasionally expressed in Schwann cells.
To test whether tumor cells express T-antigen mRNA,
Northern blot analyses were performed on cell lines derived
from both tumor types (Fig. 3a). Cell lines (41-7A, 60-28, and
60-28B) were established from a pelvic osteogenic sarcoma in
mouse Tn41-7 and from a similar tumor arising from the
dorsal vertebral arch of mouse Tn6O-28 (Table 1; Fig. 3a).
These cell lines, as well as the two Schwannoma cell lines
described above (56-24 and 64-39), were cultured in the
presence or absence of DBC prior to RNA isolation and
Northern blot analysis. Although the steady-state levels ofT
antigen mRNA varied between cell lines, this was unaffected
by DBC treatment (Fig. 3a). Cell lines 56-24, 64-39, and
60-28B express moderate levels ofT antigen mRNA, whereas
cell lines 41-7 and 60-28A express high levels (Fig. 3a). In
contrast, lacZ mRNA was not detected in these cell lines
(data not shown).
To demonstrate the presence of functional T antigen in cell
lines, coimmunoprecipitation was performed with 35S-
labeled cell extracts from the Schwannoma cell line 56-24 by
using the monoclonal antibody mAb419 (12). This antibody
coimmunoprecipitates T antigen and the tightly bound p53
protein (13). As shown in Fig. 3b, both the T antigen and p53
were coimmunoprecipitated, suggesting that functional T
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56-24 L929 SV-T2 FIG. 3. (a) Northern blot analysis of T
_
-110ft _one* antigen expression in different osteosarcoma
A_tw _ and Schwannoma cell lines derived from Tn29
mice. Early passages of the cell lines were
cultured in DMEM containing 10%o FBS. In
the cases of DBC stimulation, the cells were
cultured for 3 days in the presence ofDBC (300
,uM) prior to RNA purification. T-antigen-
negative control RNA was purified from the
brain and liver of a nontransgemc mouse.
Ethidium bromide staining of 18S and 28S
rRNA on the blot indicates relative amounts of
total RNA (20 yg per lane). T antigen-specific
hybridization probes were 32P-labeled. (b)
Coimmunoprecipitation of [35S]methionine-
labeled proteins of the 56-24 cell line, using an
anti-T antigen monoclonal antibody. Autora-
diographs are shown of immunoprecipitates
from the 56-24 cell line, the L929 cell line (T
antigen negative), and the SV-T2 cell line (a
SV40-transformed cell line). Arrows indicate
position of immunoprecipitated T antigen and
coimmunoprecipitated p53 protein. Note that
...................
neither T antigen nor p53 appeared in the
immunoprecipitate from the L929 cell line.
a
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antigen is present. These findings suggest that the tumors in
strain 29 mice may result from occasional expansion of a
subpopulation ofpreneoplastic cells, which express T antigen
but not the lacZ gene. Interestingly, although oligodendro-
cytes are the major site for MBP gene expression, we were
unable to detect T antigen expression in the central nervous
system, and, in the 23 transgenic animals examined, there
was no evidence of oligodendrocyte proliferation or neopla-
sia (Table 1).
DISCUSSION
In this report, we characterized a strain of MBP-SV40 T
antigen and MBP-lacZ double transgenic mice that develops
an unusual tumor pattern at 5-7 months of age. Two distinct
tumor types-osteogenic sarcomas and malignant Schwan-
nomas-appeared in these mice. The facial bones and jaw
were the most frequent sites for both bone tumors and
preneoplastic osteo- and chondroblastic lesions. Occasion-
ally, the preneoplastic lesions were in continuity with overt
sarcomas. The malignant Schwannomas were identified on
the basis of their neural location, ultrastructural features, and
expression of myelin genes.
Expression of the SV40 T antigen and lacZ transgenes was
detected in neither the central nor the peripheral nervous
system of Tn29 mice. The nature of this repression is un-
known. In contrast, functional T antigen was expressed at
various levels in cell lines derived from both malignant
Schwannomas and osteogenic sarcomas. No lacZ expression
was detected in these cell lines. Although the selective events
that led to activation of T antigen but not lacZ expression in
tumor cells are unknown, the presence of functional T
antigen in semidifferentiated Schwannoma cell lines indicates
that the transgenic MBP promoter displayed some degree of
tissue specificity. In contrast, although the MBP promoter
was expected to be transcriptionally active in both oligoden-
drocytes and Schwann cells (and oligodendrocytes express
high levels of MBP), oligodendrocyte tumors were not ob-
served in strain Tn29 transgenic mice, suggesting that signif-
icant expression of the T antigen in oligodendrocytes is
unlikely. Thus, differential expression of the exogenous MBP
promoter in the nervous system of this transgenic model may
reflect a dependence on integration site. Moreover, it is
unclear why the MBP-SV40 T antigen transgene is associated
with bone neoplasms. However, the majority of the bone
tumors appeared in the craniofacial skeleton. Both Schwann
cells and most osteo- and chrondrogenic cells in the head
arise from the neural crest (4, 5). A progenitor cell giving rise
to Schwann cells, satellite glial cells, and chondroblasts has
been identified in primary cultures of quail cephalic neural
crest cells (14, 15). The frequent appearance of craniofacial
bone tumors and Schwann cell tumors in our study suggests
that these two tumor types may share a common lineage,
indicating that transgene expression in this model occurs in
cells that are developmentally closely related. However,
while these tumors represent a neurocristopathy, the lack of
cell lineage markers for mammalian neural crest derivatives
makes this hypothesis speculative at present. Although MBP,
Po, and SCIP mRNA were present in cell lines derived from
malignant Schwannomas, we were unable to detect such
transcripts in bone tumor-derived cell lines (data not shown).
The Schwannoma-derived cell line 56-24 expresses mod-
erate levels of both MBP and Po mRNA in the absence of
DBC or neurons. Using a semidifferentiated Schwannoma
cell line, Gandelman et al. (16) showed that the effects of
cAMP agonists on MBP and Po mRNA are biphasic, with
myelin gene expression stimulated at low doses and re-
pressed at high doses. In contrast, cAMP agonist concentra-
tions in the range that repress myelin gene expression are
necessary for induction of galactocerebroside (a lipid char-
acteristic of myelin) expression in cultured Schwann cells
(17). Hence, the effect of cAMP agonists on cultured
Schwann cells appears complex and pleiotropic. We found
substantial downregulation of both Po and MBP mRNA
expression in the Schwannoma-derived cell line 56-24 in the
presence of a high concentration of DBC (3 mM). This
downregulation correlated with upregulation of SCIP expres-
sion. SCIP is a POU domain-containing transcription factor
that is upregulated by cAMP agonists in cultured Schwann
cells (10). This transcription factor acts in vitro as a repressor
of both the Po and MBP promoters and has a proposed role
in downregulation of these promoters during myelin break-
down in Schwann cells following nerve injury (11). Our
results are consistent with SCIP acting in negative regulation
of MBP and Po gene expression in Schwann cells.
An interesting feature of strain 29 transgenic mice is the
occasional appearance of osteogenic lesions in the ribs and
vertebral column but their virtual absence in the appendicular
skeleton. The vertebral column and its processes (arches aiqd
ribs) are generally regarded as mesodermal, being generated
from somite and axial mesenchyme (18). Neural crest cells
are numerous in the rostral portion of the somite mesen-
chyme (sclerotome) as well as in the axial mesenchyhne,
where they contribute neurons and Schwann cells to the
developing dorsWi root ganglia (19). While engulfed in a
skeletogenic environment, a subset of these trunk neural
crest derivatives could differentiate into bone/cartilage-
forming cells and contribute to the vertebral column and
processes. Experimental proof for this hypothesis awaits
future investigation.
Readily established cell lines from strain 29 transgenic mice
may be a valuable tool in the search for markers that identify
mammalian neural crest derivatives.
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